Catalin® (Catalin®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePyreneoxinPyreneoxin
Similar drugsTo uncover
  • Catalin®
    pills d / eye 
    Senzu Pharmaceutical Co., Ltd.     Japan
    • Dosage form: & nbsp

    tablets for the preparation of eye drops complete with a solvent

    Composition:

    For 1 tablet and 15 ml of solvent:

    Active pill component: pyreneoxy sodium monohydrate (in terms of pyreneoxin 0.75 mg) - 0.85 mg.

    Auxiliary components of the tablet: acid aminoethylsulfonic (taurine) - 62 mg, boric acid - 12.15 mg.

    Solvent components: boric acid 180 mg, sodium borate -1.2 mg, potassium chloride 24 mg, methyl parahydroxybenzoate 3 mg, propyl parahydroxybenzoate 1.5 mg, purified water up to 15 ml.

    Description:

    Tablets from orange-red to yellow color complete with a transparent colorless solvent. After dissolving the clear solution from orange-red to yellow.

    Pharmacotherapeutic group:Cataracts treatment tool
    ATX: & nbsp

    S.01.X.A   Other drugs for the treatment of eye diseases

    Pharmacodynamics:Catalin has the inhibitory effect of the action of quinone compounds, the process of fat oxidation and the action of aldose reductase and inhibits the progress of cataracts. The data are presented on the basis of the quinoid theory, the results are obtained on guinea pigs.
    Pharmacokinetics:

    The action of quinone substances,produced as a result of an abnormal metabolism of aromatic amino acids, stimulates the transformation of the water-soluble protein in the lens to insoluble, as a result of which the lens material becomes cloudy. Inhibiting the action of quinone substances, pyrene oxide prevents the development of cataracts. Based on the data on the study of radiolabeled hydrogen, when the rabbits of the Katalin preparation are instilled in the eyes, the concentration of pyreneoxin in the lacrimal fluid is 2 hours after instillation is 0.0189 μg eq / ml, the maximum concentration after 4 hours after instillation is 0.003 μg eq / ml .

    Indications:

    The initial stages of senile cataract.

    Contraindications:

    Individual intolerance. Child age, due to insufficient safety data.

    Pregnancy and lactation:

    Due to the lack of sufficient studies to date, the drug is not recommended for use during pregnancy and during breastfeeding.

    Dosing and Administration:

    Apply only by instillation. Immediately before use, dissolve one tablet in 15 ml of solvent and instill 1-2 drops of solution 3-5 times a day into the conjunctival bag.

    The duration of the course of treatment is determined by the doctor.

    The method of preparation is shown in the figure.

    1. Remove the white large cover from the vial with the solvent. If a film forms on the opening of the neck of the vial, gently press the vial until it disappears.

    (Please note that touching the place where the blister breaks the film will cause the tablet to get wet, which will cause difficulty in placing the tablet inside the vial).

    2. Without touching the fold line near the arrow, crack the blister with the tablet, as shown in the picture.

    3. Place the tablet in the vial directly from the blister, without touching the tablet.

    4. Tighten the white cover tightly and shake vigorously to dissolve the tablet.

    5. Before instilling, remove the brown small cover, leaving the white large lid closed, otherwise the prepared solution may pour out.

    Side effects:

    Diffuse superficial keratitis, blepharitis, conjunctival hyperemia, pruritus, burning pain in the eye, contact dermatitis, conjunctivitis, irritation, lacrimation, discharge from the eyes, a feeling of discomfort and foreign body in the eye, blurred vision.There may be allergic reactions due to the presence of parabens in the preparation. If undesirable reactions occur, the drug should be discontinued.

    Overdose:

    To date, cases of overdose have not been documented.

    Interaction:

    Drug interaction has not been studied. In case of use with other local ophthalmic preparations, the interval between their use should be at least 5 minutes. It is not recommended to apply simultaneously with eye drops containing metal ions (solutions of silver, collargol, zinc sulfate), since Catalin changes color in their presence.

    Special instructions:

    When digging in, do not touch the tip of the eye bottle.

    If you instill the solution immediately after removing the vial from a cool place, especially when there is a small amount of solution remaining in the vial, the solution may not pour out drip but be jetted. This effect is due to the expansion of cool air in the vial under the influence of the hand's heat flask. To avoid this effect, you must warm the bottle holding it in your hand for a while before instillation.

    Effect on the ability to drive transp. cf. and fur:

    Until now, the possibility of drug influence on the ability to drive vehicles has not been established.

    Form release / dosage:

    Tablets for the preparation of eye drops of 0.75 mg complete with a solvent of 15 ml.

    Packaging:

    1 tablet in a foil blister of aluminum and PVC film and 15 ml of clear solvent into a polypropylene amber-yellow bottle is placed together with the instruction for use in a cardboard pack.

    Storage conditions:

    Store at a temperature not exceeding 25 ° C. Do not freeze.

    After dissolution, store in a dark place at a temperature of no higher than 15 ° C.

    Keep out of the reach of children.

    Shelf life:

    5 years. After dissolution, use within 20 days.

    Terms of leave from pharmacies:On prescription
    Registration number:П N012592 / 01
    Date of registration:12.12.2008 / 30.08.2016
    Expiration Date:Unlimited
    The owner of the registration certificate:Senzu Pharmaceutical Co., Ltd.Senzu Pharmaceutical Co., Ltd. Japan
    Manufacturer: & nbsp
    Representation: & nbspIskra Industry Co., Ltd.Iskra Industry Co., Ltd.Japan
    Information update date: & nbsp26.12.2017
    Illustrated instructions
    Instructions
    Up